title: We need to determine who benefits most from flu treatments.
authors.affiliation: University of Edinburgh, Edinburgh EH9 1QH. s0198608@sms.ed.ac.uk
authors.forename: Lucy
authors.initials: L
authors.lastname: Hansen
mesh_terms: D000081:Acetamides / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006146:Guanidines; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000517:prevention & control; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D053139:Oseltamivir; D011714:Pyrans; D012794:Sialic Acids / Q000627:therapeutic use; D053243:Zanamivir
chemical_list: D000081:Acetamides; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir